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1. Introduction 
Smooth muscle cells (SMCs) are found in many organs, including the blood vessels, trachea, 
stomach, small intestine, and uterus. SMC-like cells are found in some other organs, for 
example, hepatic stellate cells in the liver and mesangial cells in the kidney. These SMCs and 
SMC-like cells play an important role in the formation and function of the cardiovascular, 
digestive, respiratory, and urinary systems. Vascular SMCs, which generally exist in the 
tunica media, constitute a large portion of cells in blood vessels. A main function of vascular 
SMCs involves maintaining vessel structure by involving vessel contractile and relaxation 
activities to control blood pressure. 
Vascular SMCs of each region are developed from different origins [1]. Vascular SMCs of 
large arteries near the heart originate from the neural crest cells of ectodermal origin, 
whereas other vascular SMCs are believed to differentiate from mesodermally derived 
mesenchymal cells. Among the mesodermally derived vascular SMCs, coronary SMCs are 
reported to come from the proepicardial organ [2]; and vascular SMCs of the root of the 
pulmonary artery and the lung artery stem from the second heart field [3]. Undifferentiated 
cells differentiate into progenitor cells or immature cells and ultimately differentiate into 
vascular SMCs with contractile ability. 
Vascular SMCs show different phenotypes according to external conditions, such as 
developmental stage, angiogenesis state, and disease. Vascular SMCs existing within the 
tunica media are normally called contractile SMCs. On the other hand, vascular SMCs that 
are found in disease, the fetal period, and angiogenesis are called proliferative SMCs (Fig. 1). 
Proliferative SMCs have less contractive ability than contractile SMCs because of the lack of 
sufficient myofibrils inside the cells. Proliferative SMCs have the ability to proliferate and 
migrate, and they actively synthesize proteins and secrete extracellular matrices (ECMs) like 
collagen and elastin. 
Current Basic and Pathological Approaches to  




Figure 1. Phenotypes of vascular SMCs. There are 2 phenotypes of vascular SMCs, immature prolifera-
tive SMC and differentiated contractile SMC. Vascular SMCs transform their phenotypes in response to 
the surrounding environment. Proliferative immature SMCs have abilities to proliferate, migrate, and 
synthesize proteins well. On the other hand, contractile fully differentiated SMCs adhere each other and 
have contractile ability.  
Because contractile SMCs change their phenotype into proliferative SMCs in response to the 
surrounding environment or growth factors and proliferative SMCs turn into contractile 
SMCs according to the surrounding environment, vascular SMCs are considered a unique 
cell type [4]. Proliferative SMCs and immature SMCs seen during the developmental period 
are considered identical. Therefore, the transformation from contractile SMCs to prolifera-
tive SMCs is considered the dedifferentiation process, whereas the transformation from 
proliferative SMCs to contractile SMCs is considered the differentiation process. These phe-
notype alterations of vascular SMCs are important for the regulation of angiogenesis, blood 
vessel remodeling, and homeostasis. In this chapter, we review the observation of regulato-
ry mechanisms of the differentiated phenotypes of vascular SMCs. 
2. Regulation of the vascular SMC phenotype in vitro by ECM 
When contractile SMCs are collected from a body and cultured in vitro, they immediately 
transform into proliferative SMCs and then begin to proliferate under in vitro conditions. 
These transformed cells show the same characteristics as the proliferative SMCs in vivo, 
such as the inability to contract and secrete ECMs [5]. This transformation process decreas-
es the expression of various actin-associated molecules that are seen in contractile SMCs 
and simultaneously increases the expression of proliferation-related proteins. On the other 
hand, it is difficult to retransform undifferentiated proliferative SMCs into contractile 
SMCs in vitro. 
Many researchers have attempted to achieve the retransformation of proliferative SMCs into 
contractile SMCs. Koyama et al. reported that proliferation of the undifferentiated 
proliferative SMCs can be inhibited by culturing on type Ι collagen gel [6]. Pauly et al. 
reported that culturing proliferative SMCs on Matrigel extracted from basal lamina-like 
matrix, a product from mouse Engelbreth-Holm-Swarm tumor, enables the inhibition of 
proliferation and induction of differentiation [7]. These studies suggest that regulation of the 
vascular SMC retransformation has the potential to be achieved through control of their 
ECM conditions. 
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Hayashi et al. reported that during a primary culture of chick gizzard SMCs or rat aortic 
vascular SMCs, the in vivo contractile state can be maintained by seeding cells on laminin-
coated dishes and adding insulin or insulin-like growth factor-1 (IGF-1) to the serum-free 
medium [8, 9]. However, once proliferative SMCs are transformed in vitro and then induced 
by the addition of a serum, platelet-derived growth factor-BB (PDGF-BB), or 
lysophosphatidic acid (LPA) to the maintaining medium, they do not redifferentiate into the 
contractile state despite being cultured under the previously mentioned condition [8, 10]. 
These studies suggest that SMC dedifferentiation is regulated by the extracellular 
environment and that extracellular signaling is an important factor in this differentiation 
and dedifferentiation process [8, 11]. 
Hirose et al. successfully induced redifferentiation of normal human aorta proliferative 
SMCs that were once dedifferentiated in vitro into a contractile state by culturing them on 
type IV collagen gel [12]. According to this report, SMCs take an elongated spindle-like 
structure and constructed network when cultured on type IV collagen gel (Fig. 2). At the 
same time, the expression levels of molecular markers of contractile SMCs, smooth muscle 
myosin heavy chain (SM-MHC) and smooth muscle α-actin (SM-α-actin), were increased, 
whereas comparable levels in proliferative SMCs were negligible or undetectable. 
Furthermore, elongated SMCs on type IV collagen gel could contract in response to 
stimulation by endothelin-I, a vessel contracting factor. Most important is that these 
phenomena were also observed under serum-added conditions. Primary SMC-like rat 
hepatic stellate and human kidney mesangial cells also showed elongated and network 
structures on type IV collagen gel [13]. These studies showed that it is possible to induce 
redifferentiation of proliferative SMCs into contractile SMCs in vitro and that the 
redifferentiation can be regulated by extracellular environments, especially by type IV 
collagen gel. 
 
Figure 2. Morphology of human aortic vascular SMCs on different substrates. Proliferative normal 
human vascular SMCs cultured on polystyrene culture dish or type IV collagen gel. The cells spread 
flatly on culture dish. On the other hand, once proliferated SMCs on type IV collagen gel elongate and 
form mesh-like multicellular network by formation of cell-to-cell junction. This morphology is a charac-
teristic of contractile phenotype of SMCs. 
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SMCs produce and deposit basal lamina components in their extracellular surroundings 
in vivo. They are covered by basal lamina and adhere to each other via the surrounding 
basal lamina. Major components of the basal lamina include type IV collagen, laminin, 
and proteoglycans like perlecan and nidogen. Type IV collagen is expected to work as a 
skeletal protein that consists of a micro meshwork at the basal lamina [14]. Therefore, the 
above-mentioned studies obviously indicate that the components of the basal lamina, 
especially type IV collagen, play an important role in maintaining the contractile state of 
SMCs in vivo. 
Hirose et al. reported that when human proliferative SMCs were cultured on dishes coated 
with nongel type IV collagen, the cells retained their proliferative phenotype [12]. Hayashi 
et al. examined the detailed behavior of human proliferative SMCs on type IV collagen ag-
gregates with a continuous change in the physicochemical properties [13]. They made a 
unique cell culture substrate, a hat-like-shaped gel on a cover glass using a type IV collagen 
solution. The central region of the hat-like-shaped gel has a domed gel structure surrounded 
by a broad brim-like region that consisted of a nongel form of type IV collagen aggregates. 
The proliferative SMCs in the domed gel region retained their initial round cell shape at the 
initial stage of culture (6 h) and eventually formed a multicellular meshwork at a later stage 
(24 h), as is seen with redifferentiated SMCs. However, the cells at the brim region started to 
adhere, spread, and proliferate soon after seeding. These results suggest that the physico-
chemical state of type IV collagen determines the vascular SMC phenotypes and that the gel 
form of type IV collagen, in particular, is essential to the induction of the redifferentiation of 
proliferative SMCs. Reports of inhibited proliferation of SMCs on type I collagen gel [6] and 
Matrigel [7] described earlier also indirectly imply the importance of the gel’s physicochem-
ical properties. 
What factor of the gel form of type IV collagen supports redifferentiation of proliferative 
SMCs? As described previously, the proliferative SMCs cultured on dishes coated with type 
IV collagen aggregates remained in the proliferative state [12, 13]. It is assumed that the 
mechanical property of gel exercises an effect on SMC state. Some mechanical receptors that 
actually sense various mechanical stresses, such as shear stress, are found [15, 16]. Cells may 
also have made an essential morphological change as a result of transition to the physically 
steady state. It was revealed that the mechanical properties of ECMs have significant effects 
on cell proliferation or differentiation [17]. By changing the stiffness of a culture substrate, 
for example, the differentiation of mesenchymal stem cells into many kinds of cells can be 
controlled [18]. This finding implies that the ECM is not merely a functional molecule but 
works as an important factor for cell phenotype as a physical substrate. Thus, regulation of 
the dedifferentiation and redifferentiation of the vascular SMC phenotype by ECM is as-
sumed to be a result of the ECM’s physicochemical properties. 
3. Regulation of gene expression of vascular SMC 
Studies to clarify the regulatory mechanism of vascular SMC gene expressions have been 
performed by many researchers. Contractile SMCs express unique marker proteins, such as 
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SM α-actin, SM-MHC, SM22α (also kown as transgelin), high-molecular weight caldesmon 
(h-caldesmon), and calponin [19]. On the other hand, increased protein expressions, such as 
low-molecular weight caldesmon (l-caldesmon), c-fos, Egr-1, epiregulin, and SMemb MHC, 
are seen in proliferative SMCs [19, 20]. 
A promoter analysis of these proteins has revealed the associated transcription factors 
and their binding sites that regulate the protein expressions unique to contractile  
SMCs. The CArG box (CC(A/T)6GG), one of these sites [19, 21], exists in the promoter 
region of proteins like SM22α, SM-MHC, SM α-actin, calponin, and caldesmon. It has 
been clarified that the expressions of contractile SMC-specific proteins are induced 
when the serum response factor (SRF), a ubiquitously expressed transcription factor, 
binds to the CArG box [19, 21]. Other than that, the E-box, a GATA-binding site, and an 
A/T-rich element are reported to regulate the gene expressions specific to contractile 
SMCs [22-24]. 
SRF was thought to be the main regulator of the SMC differentiation and dedifferentiation 
process because the CArG boxes exist in the promoter regions of most proteins expressed in 
contractile SMCs. However, the CArG boxes are found in the promoter region of proteins 
like c-fos or Egr-1, which are actively expressed by proliferative SMCs, and these proteins 
were also found to be regulated by the CArG box and SRF [25, 26]. These bipolar regulations 
of CArG box and SRF for the vascular SMC phenotypes have been given further 
explanations by the participation of transcriptional cofactors for SRF. In other words, SRF 
cofactors activate the gene expression specific to contractile SMCs either positively or 
negatively [27, 28]. 
The myocardin-related transcription factor (MRTF) family is attracting attention as the most 
sensible candidate for SRF cofactors that regulate vascular SMC differentiation the most 
[29]. The MRTF family consists of 3 SRF coactivators: myocardin, MKL1 (also called MAL, 
BSAC, or MRTF-A), and MKL2 (also called MAL16 or MRTF-B) [29-33]. Cysteine-rich pro-
teins, CRP1 (also called CSRP1) and CRP2 (also called CSRP2 or SmLIM), were also reported 
to be SRF cofactors that promote contractile SMC-specific gene expression [34]. CRP1 and 
CRP2 associate with SRF and GATA proteins, forming SRF-GATA-CRP1/2 complexes that 
strongly activate SMC-specific gene targets [34]. Moreover, it is reported that SRF-Nkx3.2-
GATA6 complex increases the SMC gene expression in chick gizzard SMCs [23]. As just 
described, several SRF cofactors have been reported to strongly activate the SMC-specific 
gene expression. These cofactors are assumed to play some roles in vascular SMC develop-
ment and differentiation. 
In addition, some cofactors, such as Elk-1, were reported to activate the expressions of 
specific proliferative SMC genes [35]. Elk-1 is a downstream protein of extracellular 
signal-related kinase (ERK) of mitogen-activated protein kinase (MAPK), whereas ERK 
directly activates it via phosphorylation [36, 37]. As Elk-1 binds to the Ets site on the 
genome as soon as it associates with SRF binding to the CArG box, it regulates the gene 
expression through promoters that have Ets site near the CArG box. Elk-1-induced gene 
expression activates several proteins, including c-fos [25]. Factors, such as serum or LPA, 
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that transform contractile SMCs into proliferative SMCs are thought to activate Elk-1 
through MAPK and promote the gene expressions of proliferation-associated proteins, 
such as c-fos. 
Thus, it is widely accepted that the gene expressions involved in the SMC phenotype 
regulation are controlled by many cofactors through the transcriptional factor SRF, but it 
remains unclear how each factor functions in vivo. 
4. Gene regulation by MRTF family 
The MRTF family interacts with SRF and potently enhances the expression of SRF-
dependent SMC genes. Myocardin is specifically expressed in the cardiac and circulation 
organs, whereas MKL1 and MKL2 expressions are widely distributed over various organs 
[29]. Myocardin-deficient mice died in the embryo stage, and vascular SMC differentiation 
was not observed [38]. MKL1 null mice were born normal and bore children but exhibited 
failure to nurse their offspring because the mammary myoepithelial cells were 
undifferentiated [39, 40]. MKL2 null mice had cardiovascular system defects, and the 
coronary SMCs that originated from the neural crest were undifferentiated [41, 42]. These 
results suggest that the MRTF family is widely involved in regulation of the SMC 
phenotype. Among the members of the MRTF family, MKL1 and MKL2, but not myocardin, 
are directly activated via the Rho-actin pathway [43, 44]. Myocardin and MKL1 strongly 
activate CArG box-dependent SMC gene transcription [29], whereas MKL2 is less effective 
in activating the SMC gene. 
The MRTF family has many conserved domains (Fig. 3). The MRTF family binds to the 
MADS domain of SRF by the basic rich 1 (B1) domain, and the glutamine-rich (Q) domain 
supports this binding [45]. A powerful transcription activation domain (TAD) exists on the 
c-terminus region and functions with heterologous promoters [46]. Although the MRTF 
family and SRF bind singularly, the MRTF family forms a homo/heterodimer via the 
conserved leucine zipper (LZ) domain [43, 47] and preferentially binds SRF as a dimer, 
which then forms a dimer on the CArG box [48]. 
Myocardin is reported to regulate histone acetylation by binding p300 histone 
acetyltransferase and deacetylation by binding to class II histone deacetyltransferase [49]. 
The p300 histone acetyltransferase and the class II histone deacetyltransferase interact with 
the TAD and Q domains of myocardin, respectively. The N-terminus region of MKL1 
directly binds to SPT16 and SSRP1, which are components of the facilitating chromatin 
transcription (FACT) complex [50]. The FACT complex functions as a histone chaperone and 
allows RNA polymerase II to traverse the nucleosomes by removing a H2A/H2B dimer [51]. 
Altering the repressive nature of the chromatin is necessary for the cell to implement all of 
the nuclear activities of the chromatin. Therefore, expression of the nucleosomal SMC-
related gene is assumed to be activated by the MRTF family (Fig. 4). In this manner, the 
MRTF family positively and negatively regulates the nucleosomal dynamics of the SMC-
specific gene. 
 




Figure 3. Structure of MRTF family. RPEL, RPEL motif; B1 and B2, basic region; Q, glutamine-rich 
domain; LZ, leucine zipper domain; TAD, transcription activation domain. The numbers on the right 
side indicate the number of amino acids in each protein. 
 
Figure 4. The model for nucleosomal gene activation by MRTF family. DNA is shown schematically as 
solid lines. The nucleosomal characteristic of the chromosomal site is indicated by closed circles. RNA is 
represented as a dotted line. MRTF associates with SRF and activates transcription of the nucleosomal 
genes via recruiting the FACT complex into the coding region. The FACT complex remodels the chro-
matin structure and facilitates the progression of RNA polymerase II (RNAPII). Furthermore, MRTF 
interact with p300 and loosen the nucleosomal structure by acetylating the histone.  
The SMC gene activation function of the MRTF family can be regulated by other proteins. 
Elk-1, one of the TCF families, competitively blocks the binding of MRTF to the MADS 
domain of SRF [27, 45]. By SMC stimulation of PDGF-BB or serum, the C-terminus of Elk-1 
gets phosphorylated by ERK, and phosphorylated Elk-1 then moves into the nucleus. In the 
nucleus, Elk-1 competitively inhibits the binding of myocardin and SRF by binding to the 
MADS domain of SRF; as a result, it inhibits the myocardin-activated gene expression [27]. It 
is assumed that PDGF-BB stimulation simultaneously recruits histone deacetyl transferase 
(HDAC) to the CArG box of the SMC-specific region, the acetyl group in histone H4 gets 
deacetylated by HDAC, and the promoters finally reach a stable “silencing state” [28]. 
Phosphoinositide-3-kinase (PI3K) and AKT signaling from insulin/IGF-1 is essential for 
maintaining primary culture of the chick gizzard contractile SMC phenotype [9]. Inhibiting 
the PI3K-AKT signal induces dedifferentiation of the contractile SMCs into the proliferative 
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phenotype [9]. Especially in once-dedifferentiated proliferative SMCs, insulin receptor 
substrate 1 (IRS-1) gets phosphorylated by insulin/IGF-1 signaling, although IRS-1 
phosphorylates Grb-2/SOS but not SHP-2 [11]. The different downstream molecules are then 
activated between the contractile and proliferative SMC states. Signaling from insulin/IGF-1 
through PI3K-AKT promotes nuclear exports of Foxo4, which binds to myocardin in the 
nucleus and inhibits myocardin-activated transcription [52]. Therefore, PI3K-AKT signaling 
from insulin/IGF-1 enables myocardin function as an SRF cofactor in the nucleus to maintain 
the contractile state of SMCs. 
5. CRP2 contributes to SMC differentiation 
CRP family proteins consist of 2 LIM domains and 2 glycine-rich regions (Fig. 5). The LIM 
domain is a double zinc finger-like structure that mediates protein-protein interactions. The 
CRP family proteins CRP1, CRP2, and CRP3/MLP share high sequence homology [53]; 
however, their gene expression patterns differ. CRP1 is expressed in organs such as the 
arteries, stomach, and intestines, all of which contain abundant SMCs [54]. CRP2 is mainly 
expressed in vascular SMCs and is also found in the cardiac muscle in the developmental 
period [55]. CRP3 expression was confirmed in the striated heart and skeletal muscles [56]. 
As evidenced by their expression patterns, the CRP members are reported to be related to 
muscle cell differentiation [34, 55, 57]. CRP2, in particular, plays a role in the vascular SMC 
differentiation and dedifferentiation process. CRP2 expression is known to decrease when 
vascular SMCs dedifferentiate and proliferate in response to injury [58]. On the other hand, 
CRP2-deficient mice develop normally, and the expressions of the SMC-related proteins SM 
α-actin, SM22α, and calponin neither increase nor decrease [59]. In the CRP2-deficient mice, 
however, the effect of intimal regeneration or hypertrophy increases, which occurs when 
blood vessels gets injury. When vascular SMCs from wild-type and CRP2-deficient mice 
were stimulated by PDGF-BB in vitro, there were no differences in proliferation, but the 
migration ability was reported to be increased in CRP2-deficient mice.  
 
Figure 5. Structure of CRP. Gly, glycine rich region. CRP consists of two LIM domains and two glycine 
rich regions. The LIM domain is a double zinc-finger like structure. 
CRP2 localizes in the cell nucleus and cytoplasm, where it associates with the actin 
cytoskeleton [34, 60]. In chick embryo proepicardial cells, which are progenitor cells of 
SMCs in the coronary artery, endogeneous CRP2 localizes to the nucleus, whereas CRP2 
translocates to the cytoskeleton as these cells fully differentiate into SMCs [34]. It is believed 
that CRP2 plays different roles in these different locations. In the nucleus, CRP2 associates 
with GATA proteins and SRF (CRP2-GATA-SRF) and acts as a transcriptional regulator of 
SRF-dependent SMC genes [34, 61]. On the other hand, in the cytoplasm, CRP2 directly 
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associates with actin filaments, α-actinin, and zyxin in vitro [60, 62]. CRP1 also directly 
associates with actin filaments in vitro and in vivo and stabilizes actin filament formation in 
vitro [63, 64]. The distinct role of CRP2 in the cytoplasm is unclear, but CRP2 may be 
involved in the assembly and maintenance of the actin cytoskeleton in vascular SMCs. 
We recently focused on the dynamics of CRP2 localization with respect to actin stress fiber 
formation during vascular SMC differentiation [65]. The vascular SMC differentiation pro-
cess is a characteristic of the epithelial-to-mesenchymal transformation (EMT) [66]. The 
CRP2 localization dynamics during SMC differentiation is regulated by actin stress fiber 
formation accompanied by the EMT. In particular, nuclear CRP2 distribution is determined 
by the actin polymerization state [65]. These CRP2 localization dynamics can be interpreted 
from a simple in silico CRP2 localization kinetic model regulated by actin dynamics [65]. 
Reorganization of the actin cytoskeleton is able to affect vascular SMC differentiation pro-
gress through SRF activation and CRP2 translocation. The effects of cytoplasmic CRP2 for F-
actin become more important for vascular SMC differentiation. We now speculate that actin-
bound CRP2 plays direct and indirect roles in the stabilization of SMC differentiation. 
6. Perspective 
Phenotype alterations and differentiation of vascular SMC are important for angiogenesis, 
blood vessel remodeling, and homeostasis. These processes are regulated by extracellular 
signals. In particular, maintenance of the contractile SMC phenotype is highly supported by 
the basal lamina physicochemical properties, which are probably sensed by the actin cytoskel-
eton. On the other hand, vascular SMC differentiation and SMC-related gene expression are 
highly regulated by actin dynamics. Nuclear accumulation of MKL1 and MKL2 is controlled 
by the amounts of G-actin pool, and stimulation of F-actin formation activates contractile 
SMC-related gene expression by interacting with SRF and nuclear importing MKL1 and 
MKL2. However, the gene activation function of myocardin, the most important transcription 
factor of vascular SMC differentiation, is blocked competitively by Elk-1, which is activated by 
the extracellular signaling of serum and PDGF-BB. CRP2 localization is regulated by actin 
stress fiber formation, and nuclear and cytoplasmic CRP2 play a role in SMC differentiation. 
Therefore, the actin cytoskeleton is a key factor for vascular SMC differentiation and maintain-
ing the contractile SMC phenotype. However, the details of the regulatory mechanism and 
process of SMC differentiation, as well as maintenance of the SMC phenotype, remain unclear. 
Future studies will address the integrated interrelationship among factors including ECM, 
extracellular signaling, actin dynamics, and SRF cofactors in the process of SMC differentiation 
and phenotype maintenance. 
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